End-of-day quote
Korea S.E.
07:00:00 2024-03-26 pm EDT
5-day change
1st Jan Change
14,430
KRW
-2.70%
-1.70%
-15.56%
Sales 2022
6.59B
4.88M
Sales 2023
6.5B
4.82M
Capitalization
166B
123M
Net income 2022
-6.84B
-5.07M
Net income 2023
-2.84B
-2.11M
EV / Sales 2022
15.1
x
Net cash position
2022
43.26B
32.05M
Net cash position
2023
40.59B
30.08M
EV / Sales 2023
19.3
x P/E ratio 2022
-20.8
x
P/E ratio 2023
-58.5
x
Employees
-
Yield 2022 *
-
Yield 2023
-
Free-Float
77.46%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Anterogen.Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-05-11
CI
Anterogen.Co.,Ltd. announced that it has received KRW 16 billion in funding from Shinhan Venture Investment Co, Ltd., NH Investment & Securities Co., Ltd., Investment Arm, SL Investment
21-03-07
CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 16 billion in funding from Shinhan Venture Investment Co, Ltd., NH Investment & Securities Co., Ltd., Investment Arm, SL Investment
21-03-04
CI
Anterogen.Co.,Ltd. announced that it has received KRW 12 billion in funding
20-04-23
CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 12 billion in funding
20-04-22
CI
An unknown buyer acquired 3.37% stake in Anterogen.Co.,Ltd. for KRW 10 billion.
20-03-25
CI
Anterogen.Co.,Ltd. announced that it has received KRW 4.9999992 billion in funding from Samsung Securities Co. Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm, NH Investment & Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, KB Securities Co., Ltd., Investment Arm
19-11-06
CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 4.9999992 billion in funding from Samsung Securities Co. Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm, NH Investment & Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, KB Securities Co., Ltd., Investment Arm
19-10-24
CI
Anterogen.Co.,Ltd. announced that it has received KRW 13.999979 billion in funding from EM-Tech. CO., LTD.
19-02-25
CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 13.999979 billion in funding from EM-Tech. CO., LTD.
19-02-14
CI
Anterogen.Co.,Ltd. announced that it has received KRW 6 billion in funding
19-01-31
CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 6 billion in funding
19-01-23
CI
Anterogen.Co.,Ltd. announced that it has received KRW 9.9992224 billion in funding from Samsung Securities Co. Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm
18-11-19
CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 9.9992224 billion in funding from Samsung Securities Co. Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm, and another investor
18-11-07
CI
Anterogen.Co.,Ltd. announced that it has received KRW 19.99925713 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm, KB Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm
18-10-30
CI
More news
1 day -2.70%
1 week -1.70%
Current month +2.92%
1 month +0.56%
3 months -10.37%
6 months +2.63%
Current year -15.56%
More quotes
Managers
Title Age Since
Chief Executive Officer
55
04-02-29
Chief Executive Officer
69
00-03-15
Chief Tech/Sci/R&D Officer
48
02-08-31
Members of the board
Title Age Since
Chief Executive Officer
69
00-03-15
Chief Executive Officer
55
04-02-29
Director/Board Member
70
17-02-28
More insiders
Date
Price
Change
Volume
24-03-27
14,430
-2.70%
13,336
24-03-26
14,830
+0.54%
23,114
24-03-25
14,750
+0.68%
19,805
24-03-22
14,650
+0.07%
7,896
24-03-21
14,640
-0.27%
14,772
End-of-day quote
Korea S.E., March 26, 2024
More quotes
ANTEROGEN CO.,LTD. is a Korea-based company mainly engaged in the manufacture of cell therapy products. The Company's product portfolio consists of Cupistem which is used for the treatment of Crohn's fistula by using autologous adipose-derived mesenchymal stem cells; stem cell conditioned medias (SCMs), SCM2s, and Therastem-dermas which are used for strengthening the function of skin as cosmetic raw materials; Remodullins which are used for the treatment of pulmonary arterial hypertension (PAH) and other products which are used for testing services. The Company distributes its products within domestic market.
More about the company
1st Jan change
Capi.
-15.56% 104M +0.44% 90.27B +10.00% 44.05B -16.40% 31.45B +44.36% 23.35B -8.10% 16.72B -25.64% 15.09B -9.03% 12.82B -9.37% 11.95B +98.58% 7.67B
Biopharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1